Skip to contentA
Anika Therapeutics, Inc.
A
ANIKAnika Therapeutics, Inc. Q3 2019 · 10-Q
Revenue$29.70M$29.70M+10.9% vs Q3 2018 Net Income$9.20M$9.20M+21.1% vs Q3 2018 EPS Diluted$0.66$0.66+24.5% vs Q3 2018 Gross Profit$23,746,000+28.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
Operating Cash Flowderived$10,051,000−7.3% Free Cash Flowderived$9,623,000−0.1% Margins · derivedGross margin80.0%+10.9 pt vs Q3 2018
Operating margin40.6%+8.6 pt vs Q3 2018
Net margin31.0%+2.6 pt vs Q3 2018
ended Sep 30, 2019 · filed Oct 28, 2019 · 28 d after period end